|
|
|
RNA
editing is an important mechanism for regulating genetic plasticity through the
generation of alternative protein products from a single structural gene.
Substitutional RNA editing employs a variety of genetic mechanisms, the
biochemical basis of which has been elucidated following the development of in
vitro assays that recapitulate important elements of this process. There are two
types of substitutional RNA exist in mammals, namely A-to-I and C-to-U
RNA editing. The best-characterized example of C-to-U RNA editing involves the
nuclear transcript encoding intestinal apolipoprotein B (apo
B). Apo B RNA editing changes a CAA to a UAA stop codon, generating a
truncated protein, apoB48. The functional complex includes a minimal core
composed of apobec-1 and ACF, that function as an adaptor protein by binding
both the deaminase and the RNA substrate. The RNA binding proteins also include
CUGBP2 which along with Apobec-1 binds to the consensus binding sequence UUUN
(A/U) U, present in c-myc, VEGF and Cyclooxygenase-2 (COX2). Apobec-1, 236aa protein in human (chr 12p13.1) an RNA specific cytidine deaminase, is essential but not efficient for apo B editing activity, there being a requirement for other protein factor. Apobec-1 is a dimer with the composite active site assembled through interaction of each monomer; In addition it is an RNA-binding protein that binds to the consensus sequence UUUN (A/U) U located within the terminal loop of apo B RNA. But finally it forms the minimal component of the core-editing enzyme along with ACF. ACF (apobec-1 complementation factor) exists in three isoforms; the isoform 3 is a 594aa protein (65kD), when added with apobec-1 it reconstitute the editing of an apo B mRNA template. It is found to co-localize with apobec-1 and CUGBP2. It was demonstrated that CUGBP2 co-fractionates with ACF in bovine liver S-100 extracts and that its distribution in the most enriched fractions closely matches with ACF, thus leading to the assembly to apo B holoenzyme.
Rb=rabbit; m=mouse; r=rat; h=human; s=sheep; b=bovine; c=chicken; d=dog; ~CT or ~NT=near C or N-terminus. EC=Extracellular; CL=Cytoplasmic loop. ** Expected antibody crossreactivity information is mostly based upon high (>70%) sequence conservation of antigenic/control peptides in various species. When antibody crossreactivity has actually been experimentally confirmed in various species, it will be mentioned in the appropriate data sheets. "Neat Antisera or antisera" are the unpurified antiserum and it is suitable for ELISA and Western. "Affinity pure" IgG may be more suitable for immunohistochemical (IHC) applications and to reduce background in most immunological applications including ELISA and Western. "Control peptides" can not be used for Western as they are very short peptides. They are intended for ELISA or antibody blocking studies to establish antibody specificity. Western blot +ve protein controls, where available, are semi-pure, pure or recombinant proteins that are formulated in SDS-PAGE sample buffer. They are recommended to be used for Western (load 10 ul/lane) for visulaization with antibodies. All Products are for in vitro research use only. rev 40706A
| ||||||||||||||||||||||||||||||||||||||
|
|